Cargando…
Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficie...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319454/ https://www.ncbi.nlm.nih.gov/pubmed/37409256 http://dx.doi.org/10.3389/fonc.2023.1187052 |
_version_ | 1785068254884003840 |
---|---|
author | Schmitt, Antonin Royer, Bernard Boidot, Romain Berthier, Joseph Ghiringhelli, François |
author_facet | Schmitt, Antonin Royer, Bernard Boidot, Romain Berthier, Joseph Ghiringhelli, François |
author_sort | Schmitt, Antonin |
collection | PubMed |
description | Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity. |
format | Online Article Text |
id | pubmed-10319454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103194542023-07-05 Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency Schmitt, Antonin Royer, Bernard Boidot, Romain Berthier, Joseph Ghiringhelli, François Front Oncol Oncology Esophageal cancer is a cancer with poor prognosis and the standard 1(st) line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity. Frontiers Media S.A. 2023-06-20 /pmc/articles/PMC10319454/ /pubmed/37409256 http://dx.doi.org/10.3389/fonc.2023.1187052 Text en Copyright © 2023 Schmitt, Royer, Boidot, Berthier and Ghiringhelli https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Schmitt, Antonin Royer, Bernard Boidot, Romain Berthier, Joseph Ghiringhelli, François Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
title | Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
title_full | Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
title_fullStr | Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
title_full_unstemmed | Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
title_short | Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
title_sort | case report: 5-fluorouracil treatment in patient with an important partial dpd deficiency |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319454/ https://www.ncbi.nlm.nih.gov/pubmed/37409256 http://dx.doi.org/10.3389/fonc.2023.1187052 |
work_keys_str_mv | AT schmittantonin casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency AT royerbernard casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency AT boidotromain casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency AT berthierjoseph casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency AT ghiringhellifrancois casereport5fluorouraciltreatmentinpatientwithanimportantpartialdpddeficiency |